April 2024 – Page 12

Neumora’s Schizophrenia Drug Study Halted by FDA Due to Preclinical Safety Signals

1 year ago talkbio0Tagged Neumora, NMRA-266, Old World rabbit, Phase I Clinical Trials, Preclinical safety signals, Schizophrenia, Seizures, Study on Hold

Neumora Therapeutics, Schizophrenia drug study, NMRA-266, Preclinical safety signals, Convulsions in rabbits, Clinical hold, Phase I trial

Optimizing Pharmaceutical Supply Chains: The Evolving Role of Third-Party Logistics Providers

1 year ago talkbio0Tagged Administration occupational activities, Cold Chain Management, Pharma, Pharmaceutical Supply Chain, Regulatory Compliance, requirements, third-party logistics

Third-Party Logistics (3PL) Providers, Pharmaceutical Supply Chain, Pharma 4.0, Regulatory Compliance, Cold Chain Management, Data Mining and Management, Licensing Requirements

The Transformative Future of Specialist Distribution: Adaptive Strategies and Technological Innovations

1 year ago talkbio0Tagged **Last-Mile Solutions**:, Adaptive Strategies, Artificial Intelligence, Automation, Data Integration, Global Expansion, Hospital specialist, Smart Distribution Centers, Spatial Distribution, Technological Innovations, trends qualifier, Virtual Distribution

Specialist Distribution, Future Trends, Adaptive Strategies, Technological Innovations, Automation, Artificial Intelligence, Last-Mile Solutions, Virtual Distribution, Data Integration, Global Expansion, Smart Distribution Centers

Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits

1 year ago talkbio0Tagged Neumora, NMRA-266, Schizophrenia, Seizures, United States Food and Drug Administration

Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia

Life Sciences Senior Associate: Evaluating Opportunities in Therapeutics, Diagnostics, and Health Tech

1 year ago talkbio0Tagged Diagnostics, diligence, Evaluation, Life Sciences Senior Associate, research tools, Technology, Health Care

Life Sciences Senior Associate, Therapeutics, Diagnostics, Research Tools, Health Technology, Opportunity Evaluation, Diligence

Regeneron Unveils $500M Biotech-Focused Venture Capital Fund

1 year ago talkbio0Tagged biotech, Regeneron, Venture Capital Fund

Regeneron, Venture Capital Fund, Biotech, $500 million

EU Approves Illumina’s Divestment Plan for Cancer Test Maker Grail

1 year ago talkbio0Tagged cancer diagnostic subsidiary, Capitalization, Clearance, Divestment, EU, European Commission, Illumina

Illumina, Grail, EU clearance, Divestment, European Commission, Cancer diagnostic subsidiary, Capitalization terms

European Commission Grants Approval for Illumina to Divest Grail

1 year ago talkbio0Tagged Antitrust, competition, Divestment, European Commission, Illumina

Illumina, Grail, European Commission, Divestment, Competition, Antitrust

EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts

1 year ago talkbio0Tagged European Medicines Agency, Evaluation, Feeling suicidal (finding), Glucagon-Like Peptide 1, Ozempic, Wegovy

GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation

Fujifilm Diosynth Announces $1.2B Expansion in North Carolina, Aiming to Employ 1,400

1 year ago talkbio0Tagged Biopharmaceutical manufacturing, Biotechnology, CDMO facility, end-to-end cell culture, expansion, Fujifilm, Holly Springs, Investments, Japanese language, North Carolina, Occupations

Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment